Cinclus Pharma Holding AB
Clinical-stage pharma company developing a PCAB for gastric acid-related diseases.
CINPHA | ST
Overview
Corporate Details
- ISIN(s):
- SE0020388577
- LEI:
- 549300TJBPSNZ3DO6B42
- Country:
- Sweden
- Address:
- Kungsbron 1, Plan 3, trappa G, 111 22 Stockholm
- Website:
- https://cincluspharma.com/
- Sector:
- Manufacturing
Description
Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-08 08:00 |
Cinclus Pharmas linaprazan glurate har inkluderats på Kinas nationella ersättni…
|
Swedish | 87.9 KB | ||
| 2025-12-08 08:00 |
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listin…
|
English | 87.3 KB | ||
| 2025-12-08 07:30 |
Cinclus Pharma rekryterar Magnus Christensen som ny CFO
|
Swedish | 77.8 KB | ||
| 2025-12-08 07:30 |
Cinclus Pharma recruits Magnus Christensen as new CFO
|
English | 77.6 KB | ||
| 2025-12-08 07:00 |
Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)
|
English | 97.6 KB | ||
| 2025-12-08 07:00 |
Kallelse till extra bolagsstämma i Cinclus Pharma Holding AB (publ)
|
Swedish | 92.9 KB | ||
| 2025-12-01 15:25 |
Cinclus Pharmas valberedning föreslår ny representant för bolagets grundare til…
|
Swedish | 78.7 KB | ||
| 2025-12-01 15:25 |
Cinclus Pharma’s Nomination Committee proposes new representative for the compa…
|
English | 78.9 KB | ||
| 2025-11-25 08:59 | English | 15.3 MB | |||
| 2025-11-20 08:00 | Swedish | 15.6 MB | |||
| 2025-11-18 08:00 |
Cinclus Pharma's Nomination Committee for the 2026 Annual General Meeting appoi…
|
English | 79.1 KB | ||
| 2025-11-18 08:00 |
Cinclus Pharmas Valberedning för årsstämma 2026 utsedd
|
Swedish | 78.9 KB | ||
| 2025-08-29 07:30 |
Cinclus Pharma inleder fas III-studien HEEALING 1 med linaprazan glurate för pa…
|
Swedish | 89.5 KB | ||
| 2025-08-29 07:30 |
Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in …
|
English | 88.4 KB | ||
| 2025-08-20 08:00 | Swedish | 2.6 MB |
Automate Your Workflow. Get a real-time feed of all Cinclus Pharma Holding AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cinclus Pharma Holding AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cinclus Pharma Holding AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
